Shineco (SISI) Acquires Majority Stake in Biotech Firm InfiniClone | SISI Stock News

3 days ago

Shineco, Inc. (SISI, Financial) has taken a significant step in expanding its presence in the biotechnology sector. On April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong, finalized a Share Purchase Agreement to acquire a 51% equity stake in InfiniClone Limited. This acquisition marks a strategic investment in a company specializing in regenerative medicine, a rapidly growing field within the biotech industry.

InfiniClone Limited, based in Hong Kong, has been at the forefront of regenerative medicine innovation. The company focuses on cutting-edge technologies such as induced pluripotent stem cell research, which holds promise for numerous medical applications. Moreover, InfiniClone is involved in developing cosmeceuticals, merging cosmetic and pharmaceutical advancements to create skin care products with medical benefits.

This acquisition aligns with Shineco's strategy to diversify and enhance its portfolio with innovative technologies and products. With the completion of this deal, Shineco aims to leverage InfiniClone's expertise to further its commitment to providing advanced healthcare solutions.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.